title: Mouse prostate proteomes are differentially altered by supranutritional intake of four selenium compounds.
abstract: We have shown that, in contrast to selenomethionine (SeMet) or selenite, methylseleninic acid (MSeA) and Se-methylselenocysteine (MSeC) exert prostate cancer (PCa) inhibitory effect in preclinical models. Here we investigated the prostate proteome signatures of mice treated with each selenium (Se) form for hypothesis generation concerning their potential in vivo molecular targets and cancer risk modification. Nude mice bearing subcutaneous PC-3 xenografts were treated daily with each Se form (3 mg Se/kg) orally for 45 days. Five prostates were pooled from each group. Their proteomes were profiled by LC-MS/MS with iTRAQ labeling. Of the 1,088 proteins identified, 72 were significantly modulated by one or more Se forms. MSeA and MSeC each induced separate sets of tumor suppressor proteins and suppressed different onco-proteins. Proteins induced by selenite and shared with MSeC were related to energy metabolism (e.g., fatty-acid synthase), and those induced by SeMet included vimentin and heat-shock protein-70, favoring cancer growth. While proteome changes induced by MSeA were associated with PCa risk reduction, desirable risk-reducing signatures induced by MSeC were counterbalanced by risk-promoting patterns shared with selenite and SeMet. We propose that the balance of oncogenic vs. suppressor protein patterns in the prostate may impact the direction of PCa risk modification by a given selenium.
authors: The Hormel Institute, University of Minnesota, Austin, Minnesota, USA. jinhui.zhang@ttuhsc.edu
authors: Jinhui
authors: J
authors: Zhang
authors: Lei
authors: L
authors: Wang
authors: Guangxun
authors: G
authors: Li
authors: Lorraine B
authors: LB
authors: Anderson
authors: Yanji
authors: Y
authors: Xu
authors: Bruce
authors: B
authors: Witthuhn
authors: Junxuan
authors: J
authors: Lü